Liraglutide Cost in Vermont 2026: Cash Price, Medicaid, Insurance, and Compounding Options

What Does Liraglutide Actually Cost in Vermont in 2026?

Retail cash prices for liraglutide in Vermont range from roughly $750 to $1,349 per month depending on the pharmacy and dose. The manufacturer list price sits at approximately $1,349 per month, but most independent and chain pharmacies in Burlington, Montpelier, Rutland, and other Vermont communities post cash prices closer to $900 per month after standard pharmacy discounts. That gap matters. A patient paying out of pocket without any assistance program spends $10,800 per year at list price versus about $10,800 at average retail, still a substantial burden for most Vermont households.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in 2010 under the brand name Victoza for type 2 diabetes and in 2014 under Saxenda for chronic weight management in adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related comorbidity [1]. The drug works by stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways [2]. In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3.0 mg produced a mean body-weight loss of 8.0% at 56 weeks compared with 2.6% for placebo (P<0.001), with 63.2% of liraglutide-treated patients achieving at least 5% weight loss [3].

GoodRx and similar coupon platforms may bring Vermont retail prices down to $700 to $850 per month at specific pharmacies, though those coupons cannot be combined with any insurance benefit. Costco Pharmacy in Vermont historically offers competitive pricing for members. Always call ahead because pharmacy acquisition costs shift monthly.

Vermont Medicaid Coverage for Liraglutide

Vermont Medicaid (Green Mountain Care) covers liraglutide for both type 2 diabetes (Victoza) and chronic weight management (Saxenda), but prior authorization is required for both indications. The PA process for the weight-management indication typically requires documentation of a body mass index at or above 30 kg/m, evidence of a structured lifestyle intervention, and confirmation that the prescriber has ruled out secondary causes of obesity [4]. For the diabetes indication, PA reviewers generally want to see inadequate glycemic control on metformin or another first-line agent before approving liraglutide.

Vermont's Medicaid program follows the Green Mountain Care formulary managed by the Department of Vermont Health Access (DVHA). Prescribers submit PA requests through the DVHA online portal or via fax. Approval timelines average five to seven business days for standard requests; urgent requests may be reviewed within 24 hours [5]. Denied PAs can be appealed, and Vermont statute requires that Medicaid managed care organizations provide a clear written denial explanation with appeal rights outlined.

Patients who qualify for both Medicare and Vermont Medicaid (dual eligibles) may find that Medicare Part D is the primary payer. Medicare Part D coverage for GLP-1 drugs for weight management has been restricted historically, though the Biden-era proposed rule from CMS aimed to expand it [6]. Confirm current Part D formulary status directly with the specific plan before prescribing.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents in patients with type 2 diabetes who have established cardiovascular disease, high cardiovascular risk, chronic kidney disease, or obesity, supporting medical necessity arguments in PA submissions [7].

Is Compounded Liraglutide Legal in Vermont?

Compounded liraglutide is available through 503A compounding pharmacies operating in Vermont, and its preparation is legal under federal and Vermont state law provided the pharmacy holds the required licenses and the prescription is patient-specific. Section 503A of the Federal Food, Drug, and Cosmetic Act permits a licensed pharmacist to compound a drug for an identified individual patient based on a valid prescription from a licensed prescriber, even when an FDA-approved equivalent exists [8].

Vermont's pharmacy licensing body, the Vermont Secretary of State Office of Professional Regulation, requires that any pharmacy compounding sterile preparations hold a sterile compounding license and comply with USP Chapter 797 standards for sterile preparation [9]. Liraglutide is administered by subcutaneous injection, so it qualifies as a sterile preparation and must meet those standards.

The FDA has not designated liraglutide as a drug in shortage as of mid-2025, which is a meaningful distinction. During a declared shortage, 503B outsourcing facilities can compound copies of shortage drugs more broadly. Without a shortage designation, 503A pharmacies may still compound for individual patients, but 503B facilities face stricter limitations [10]. Vermont residents should confirm that any pharmacy offering compounded liraglutide holds a valid 503A sterile compounding license before filling a prescription.

Compounded liraglutide in Vermont costs approximately $150 per month, compared to the $900 average retail cash price for branded product. That $750 monthly difference represents real savings, but patients should understand that compounded preparations are not FDA-approved, batch testing practices vary by pharmacy, and the long-term safety data from clinical trials apply specifically to the branded formulations studied [3].

A prescriber writing for compounded liraglutide in Vermont must do so through a valid prescriber-patient relationship. Telehealth encounters satisfy that requirement under current Vermont law (see below).

Vermont Insurance Coverage: Private Plans and Employer Benefit

Private insurance coverage for liraglutide in Vermont varies considerably by plan type, the specific indication, and the plan year's formulary decisions. Patients should pull the current year's formulary document from their insurer's website before assuming coverage.

For type 2 diabetes (Victoza), most major commercial plans operating in Vermont, including Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna, list liraglutide on Tier 3 or Tier 4 with step therapy requirements [11]. Step therapy typically requires a documented trial of metformin and sometimes a sulfonylurea or SGLT-2 inhibitor before the plan will approve liraglutide. A prescriber can request a step therapy override if the patient has a contraindication or if a required drug was previously tried and failed.

For chronic weight management (Saxenda), coverage is less consistent. Vermont's state employee health plan and many large employer self-funded plans have historically excluded anti-obesity medications. The Treat and Reduce Obesity Act, if passed federally, would require Medicare to cover anti-obesity medications, and some private plans may follow [12]. Check the plan's "exclusions" section for language like "weight loss drugs" or "anti-obesity agents."

Patients with employer-sponsored plans governed by ERISA can appeal denials on medical necessity grounds. A letter of medical necessity from the prescribing physician, citing the ADA 2024 Standards of Care [7] or the Endocrine Society's 2015 clinical practice guideline on obesity pharmacotherapy [13], strengthens those appeals.

How the Novo Nordisk Savings Programs Work in Vermont

Novo Nordisk operates two patient assistance pathways that Vermont residents can access.

Saxenda Savings Card (commercial insurance patients): Eligible patients with commercial insurance may pay as little as $25 per 30-day supply for up to 24 months. The card is not valid for patients using Medicare, Medicaid, or any other government-funded insurance. Income limits apply and are updated annually. Enrollment is available at the Novo Nordisk patient assistance portal [14].

Patient Assistance Program (uninsured or underinsured): Novo Nordisk's NovoCare program provides Saxenda and Victoza at no cost to qualifying patients who meet income thresholds, generally at or below 400% of the federal poverty level without drug coverage [15]. Vermont residents apply online or through their prescriber's office. Processing takes two to four weeks; the prescriber must complete a portion of the form.

Victoza Savings Card: A parallel commercial savings card exists for Victoza in the diabetes indication, again restricted to commercially insured patients. Both cards require monthly re-enrollment checks and can be terminated if a patient's insurance situation changes.

Generic liraglutide is not yet available in the United States as of mid-2025. Novo Nordisk's composition-of-matter patents on liraglutide have expired in some jurisdictions, but FDA approval of a generic or biosimilar version through the 505(j) or 351(k) pathway had not been granted at the time of this writing. When a generic does reach market, Vermont's pharmacy substitution laws would permit a pharmacist to substitute it automatically unless the prescriber writes "dispense as written" [16].

Telehealth Prescribing of Liraglutide in Vermont

Vermont law permits telehealth prescribing of liraglutide provided the prescriber holds an active Vermont license and has established a valid prescriber-patient relationship through a synchronous audio-video encounter [17]. That relationship requirement means a text-only or asynchronous questionnaire alone is not sufficient under Vermont statute for controlled substances, though liraglutide is not a controlled substance. Some Vermont telehealth platforms have interpreted the non-controlled-substance rules more permissively, allowing asynchronous prescribing, but prescribers should verify current Vermont Medical Practice Act guidance before doing so [17].

Federal rules enacted during the COVID-19 public health emergency relaxed many telehealth prescribing requirements. Those flexibilities have been extended several times and remain in effect through 2025, but Vermont practitioners should monitor DEA and HHS announcements for any changes affecting their practice [18].

HealthRX operates telehealth services in Vermont. Patients complete a medical intake, upload relevant labs (HbA1c, lipid panel, comprehensive metabolic panel), and connect with a clinician via video visit. If liraglutide is clinically appropriate, the prescription is sent electronically to the patient's preferred Vermont pharmacy or to a licensed compounding pharmacy. Follow-up visits are scheduled at four to six weeks to assess tolerability and titration.

Liraglutide Dosing and Titration: What Vermont Patients Should Expect

Starting liraglutide at the full therapeutic dose causes nausea, vomiting, and diarrhea in a meaningful proportion of patients. The standard titration schedule minimizes those effects.

For Saxenda (weight management): Begin at 0.6 mg once daily subcutaneously for one week, then increase by 0.6 mg each week until reaching the target dose of 3.0 mg daily. The full titration takes four weeks [1]. If a patient cannot tolerate a dose increase, the prescriber may pause at the current dose for an additional week before escalating.

For Victoza (type 2 diabetes): Start at 0.6 mg once daily for one week, increase to 1.2 mg, and, if additional glycemic control is needed, increase to 1.8 mg. The 0.6 mg dose is a titration dose, not a therapeutic dose [1].

The LEADER cardiovascular outcomes trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced major adverse cardiovascular events (MACE) by 13% compared with placebo (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for noninferiority and P=0.01 for superiority) in patients with type 2 diabetes and high cardiovascular risk [19]. That cardiovascular benefit is an important consideration when writing PA letters for Vermont Medicaid or commercial insurance.

Adverse effects that Vermont patients and prescribers should discuss before starting include: nausea (most common, typically peaks during titration), pancreatitis (rare but requires prompt evaluation), thyroid C-cell tumors (observed in rodent studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN-2), and cholelithiasis [1]. The FDA label carries a boxed warning for thyroid C-cell tumors [1].

Comparing Liraglutide to Semaglutide for Vermont Patients

Vermont patients and prescribers frequently ask how liraglutide compares to semaglutide (Ozempic, Wegovy, Rybelsus). The comparison matters for cost, efficacy, and insurance coverage decisions.

Weight loss efficacy favors semaglutide. In STEP-1 (N=1,961), subcutaneous semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks versus 2.4% for placebo [20]. Liraglutide's SCALE Obesity trial showed 8.0% weight loss at 56 weeks [3]. That roughly six-percentage-point difference in weight loss is clinically meaningful for many patients.

Cost comparison in Vermont for 2026: semaglutide 2.4 mg (Wegovy) carries a list price near $1,349 to $1,600 per month, similar to or above liraglutide. Compounded semaglutide has faced additional FDA scrutiny following the removal of semaglutide from the shortage list in 2024, making compounded liraglutide a potentially more legally stable low-cost option in Vermont as of mid-2025 [10].

Liraglutide is dosed daily; semaglutide is dosed once weekly. Some patients prefer daily injections because a missed dose has a shorter impact window, while others strongly prefer weekly dosing for convenience. Both are subcutaneous injections using prefilled pens.

Vermont insurance formularies in 2026 differ in which agent they prefer. A patient whose plan covers liraglutide at Tier 3 but requires step therapy through liraglutide before covering semaglutide may find starting with liraglutide the fastest path to the higher-efficacy agent.

Finding the Lowest Liraglutide Price in Vermont: A Step-by-Step Approach

The following sequence gives Vermont patients a practical method for minimizing cost.

Step 1: Check your insurance formulary. Log in to your insurer's member portal and search for "liraglutide," "Victoza," and "Saxenda." Note the tier, any step therapy requirements, and the estimated co-pay.

Step 2: Request prior authorization early. If PA is required (Vermont Medicaid or many commercial plans), ask your prescriber to submit the PA before you attempt to fill the prescription. Delaying PA submission is the single most common reason patients pay cash unnecessarily for the first month.

Step 3: Apply for manufacturer savings. If you have commercial insurance, apply for the Novo Nordisk Saxenda or Victoza savings card at the time of prescribing, not after the first denial [14]. The card reduces co-pays substantially for eligible patients.

Step 4: Compare GoodRx, RxSaver, and pharmacy cash prices. Run the drug name and your Vermont zip code through at least two coupon platforms. Prices vary by $100 to $200 per month between pharmacies in the same city.

Step 5: Ask about 503A compounding. If cash price remains prohibitive and your prescriber agrees compounded liraglutide is appropriate for your clinical situation, request a prescription written specifically for a licensed Vermont 503A sterile compounding pharmacy. Confirm the pharmacy's license status with the Vermont Secretary of State before filling [9].

Step 6: Apply for NovoCare if uninsured. If you have no drug coverage and income at or below 400% of the federal poverty line, apply to NovoCare for free medication [15]. Processing takes two to four weeks, so plan ahead.

What the Endocrine Society and ADA Say About Long-Term Liraglutide Use

Clinical guidelines from the Endocrine Society and the American Diabetes Association inform how Vermont prescribers approach liraglutide for the long term.

The Endocrine Society 2015 Clinical Practice Guideline on Pharmacological Management of Obesity states: "We recommend that pharmacotherapy be used only as an adjunct to diet and physical activity interventions for patients who have not achieved weight goals through lifestyle interventions and for whom the expected benefits of treatment outweigh the risks." The guideline lists liraglutide among the agents with sufficient evidence for recommendation [13].

The American Diabetes Association 2024 Standards of Care in Diabetes note that GLP-1 receptor agonists with proven cardiovascular benefit, including liraglutide, "are recommended as part of the glucose-lowering regimen for adults with type 2 diabetes and established CVD or very high cardiovascular risk, independent of baseline HbA1c or HbA1c target" [7]. That language directly supports PA arguments for Vermont Medicaid and commercial insurance when a patient has documented cardiovascular risk factors.

Patients who discontinue liraglutide typically regain weight. In the SCALE Obesity follow-up at 160 weeks after a 12-week washout, patients who stopped liraglutide regained approximately two-thirds of the weight lost during active treatment [21]. That data point matters for Vermont patients and prescribers planning duration of therapy and anticipating insurance coverage discussions about long-term use.